MedTrace Logo

A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure

NCT02618590 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2016-03-16

No results posted yet for this study

Summary

This is a multi-center retrospective study, designing to access the best treatment strategy in non-small cell lung cancer (NSCLC) patients harboring EGFR mutant type after first/second line EGFR-TKI failure. The study end point is Progression Free Survival 2 (PFS2), which is defined as the time period from Progression Disease 1(PD1) to Progression Disease 2(PD2). PD1 is defined as the first tumor progression time from taking EGFR-TKI evaluated by Recist 1.1 criterion, and PD2 as the second tumor progression time after EGFR-TKI failure no matter what second/third line treatment was, PD2 is also evaluated by Recist 1.1 criterion.

Conditions

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • li-kun Chen, doctor · associate chief physician

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-06-30
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02618590 on ClinicalTrials.gov